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Abstract 
γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter within the central nervous system 
(CNS) with fast, trans-synaptic and modulatory extrasynaptic effects being mediated by the ionotropic 
GABA Type A receptors (GABAARs). These receptors are of particular interest since they are the 
molecular target of a number of pharmacological agents, of which the benzodiazepines (BZDs), such 
as diazepam, are the best described. The anxiolytic, sedating and myorelaxant effects of BZDs are 
mediated by separate populations of GABAARs containing either α1, α2, α3 or α5 subunits and the 
molecular dissection of the pharmacology of BZDs indicates that subtype-selective GABAAR 
modulators will have novel pharmacological profiles. This is best exemplified by α2/α3-GABAAR 
positive allosteric modulators (PAMs) and α5-GABAAR negative allosteric modulators (NAMs), which 
were originally developed as non-sedating anxiolytics and cognition enhancers, respectively. This 
review aims to summarize the current state of the field of subtype-selective GABAAR modulators acting 




1.1   γ-Aminobutyric Acid Type A Receptor (GABAAR) structure and function. γ-Aminobutyric 
acid (GABA) is the major inhibitory neurotransmitter within the central nervous system (CNS). The 
effects of GABA are exerted via activation of either the ionotropic GABA type A or metabotropic 
GABA type B receptors (GABAARs and GABABRs). GABAARs are responsible for the point-to-point 
transfer of information across the synapse but they are also located extrasynaptically, where they 
mediate a more modulatory, tonic inhibitory tone.1  They are members of the Cys-loop superfamily of 
ligand-gated ion channels2 and contain a roughly 13-residue disulphide loop within the large N-terminal 
domain that is conserved within this family which also include the nicotinic acetylcholine, serotonin 
type 3 (5HT3) and glycine receptors.3 When activated, GABAARs generally permit the flow of chloride 
ions from outside to inside the neuron (although this may be reversed early in development)4 thereby 
resulting in a hyperpolarisation of the membrane potential that reduces the probability of the neuron 
firing an action potential.  
GABAARs are heteropentamers assembled from the 19 members (α1-6, β1-3, γ1-3, δ, ε, θ, π 
and ρ1-3) of the GABAA protein family, with the most abundant forms comprising α, β and γ subunits 
in a 2:2:1 stoichiometry.5,6 The various (~25) different GABAAR subtypes that occur in the mammalian 
brain7,8 have subcellular (i.e., synaptic or extrasynaptic), region- and circuit-specific distributions that 
suggest the different subtypes are associated with distinct CNS functions.9 The binding site for the 
orthosteric ligand (GABA) is found at the interface of the α and β subunits and hence there are typically 
two GABA binding sites per heteropentamer.6,10,11,12 In addition, GABAARs have recognition sites for 
a variety of allosteric modulators, including barbiturates, alcohol, benzodiazepines (BZDs), and 
neurosteroids,13,14,15 with structural aspects of these binding sites beginning to be elucidated.16,17,18 
Recently, high-resolution cryo-electron microscopy (cryo-EM) structures of the human α1β2γ2 
and α1β3γ2 GABAARs have been reported.11,12,19 The analysis of the receptors in complexes with the 
orthosteric agonist GABA and the GABA binding site antagonist bicuculline as well as the open-
channel blocker pycrotoxin and BZD binding site ligands such as diazepam (Figure 1), alprazolam and 
flumazenil not only provide a detailed insight into the overall assembly and heteromeric interactions of 
GABAARs, but have also started to reveal the structural basis of receptor activation and allosteric 
modulation. The focus of the present review will be on compounds that bind to the BZD site with more 




Figure 1. 3D-reconstruction of the 1β3γ2-GABAAR (bound to the channel blocker picrotoxin which 
is not shown in the figure, PDB:6HUP)19. Images were generated using Maestro Version 11.9.011, 
MMshare Version 4.5.011, Release 2019-1. The 1 subunits are colored in grey (A) or green (B, C), 
β3 in blue and γ2 in yellow. A) GABAARs belong to the Cys-loop family of ligand-gated ion channels 
with each subunit being characterized by a long extracellular N-terminus, which contains the defining 
Cys-loop, and four trans-membrane domains (M1-4), two short loops that link M1-M2 and M2-M3, a 
longer intracellular loop between M3 and M4 (modulated by phosphorylation), and a small extracellular 
C-terminus. B) Side view: the heteropentameric arrangement of subunits in the 2:2:1 stoichiometry of 
α, β and γ subunits that comprise the most abundant form of GABAAR, arranged around the central 
chloride-permeable channel pore, lined by the M2 regions of the different subunits. C) Top view: two 
GABA binding sites are found at the junctions between α and β subunits while the BZD site is located 
at the interface of a γ2 and either an α1, α2, α3 or α5 (but not α4 or α6) subunit.10,11,12,17 The γ subunit 
may be replaced by a variety of less abundant subunits (e.g., δ, ε, θ or π) whereas the ρ1-3 subunit can 
form homopentameric assemblies that are also known as GABAC receptors.22 Not illustrated here are 
the multiple additional binding sites on the GABAAR that occur, for example, within the transmembrane 
region, such as the anesthetic and neurosteroid binding sites, or within the ion channel pore itself, for 
example the picrotoxin (or convulsant) binding site.  
 
1.2   BZDs are positive allosteric modulators of GABAARs. Since the introduction of 
chlordiazepoxide and diazepam in the early 1960s, and thereafter multiple other analogues including 
alprazolam and lorazepam, the BZD class of drugs has been widely used in the clinic as anxiolytics, 
sedative-hypnotics, myorelaxants and anticonvulsants.23 However, although the myorelaxant/sedative 
properties of BZDs can be useful in an anesthetic context, they represent significant side effects in the 
treatment of patients with generalized anxiety disorder (GAD). Moreover, prolonged BZD use can be 
accompanied by the development of physical dependence and a tolerance towards certain aspects of 
their pharmacology, which results, for example, in them being unsuitable for prophylactic use in 
epilepsy patients. Of the various modulators of GABAAR function, BZDs are the best characterized 
based not only upon their clinical utility but also our understanding that the BZD binding site occurs at 
the α/γ2 subunit interface when the α subunit is either an α1, α2, α3 or α5 (but not α4 or α6).17 In 
addition, compounds that bind at this recognition site can modulate GABAAR function in a bidirectional 
manner with compounds producing either positive or negative allosteric modulators (PAMs and NAMs) 
that result in a shift to the left or right, respectively, of the GABA concentration-effect curve. Hence, a 
PAM increases and a NAM decreases the apparent affinity of the GABAAR for GABA. In addition, 
ligands such as flumazenil (23, Figure 9) may bind to the BZD binding site but be functionally silent in 
that they produce no physiological response. Such compounds can be described either as neutral 
allosteric modulators or site silent binders at or competitive antagonists of the BZD site and it is this 
latter nomenclature that we will use in the current manuscript.  
 
 
Figure 2. Details of the architecture and schematic representations of the main interactions of 
flumazenil (A and C, PDB:6D6U) and diazepam (B and D, PDB:6HUP) in the BZD binding site of 
α1β2γ2 and α1β3γ2 GABAARs, respectively. Images have been generated using Maestro Version 
11.9.011, MMshare Version 4.5.011, Release 2019-1. A, B) 1 subunit is colored in light blue while 
γ2 is golden. H-bonds are in yellow dots, halogen bonds in purple dots, π-π stacking in blue dots; C, D) 
Representations of the aminoacidic residues principally involved in the interaction with BZDs in a 3Å-
range. H-bonds are in purple arrows, halogen bonds in yellow arrows, π-π stacking in green arrows. 
 
The so-called classical BZDs are non-selective PAMs that potentiate the effects of GABA at 
the different GABAAR subtypes (i.e., α1-, α2-, α3- and α5-GABAARs) with equivalent affinity and 
efficacy.19 The structural characterization of GABAARs has opened up the way for the analysis of 
ligands interactions in the BZD binding site (Figure 2), although the correlation between specific 
interactions and the efficacy profile of GABAARs modulators has not yet been fully investigated. 
1.3   Different GABAAR subtypes have distinct functions. In order to develop compounds that retain 
efficacy but have a reduced side effect liability compared to BZDs, it is important to understand which 
of the various pharmacological features of BZDs can be attributed to specific subtypes of the GABAAR. 
In this regard, molecular genetic studies with α-subunit knock-out and point-mutation mice and 
medicinal chemistry approaches that selectively target particular subtypes, have led to the general 
concept that α1-GABAARs mediate the sedative effects of BZDs, whereas α2- and/or α3-GABAARs are 
associated with anxiolysis and α5-GABAARs play a role in cognitive processes and learning.24 Evidence 
that the α1 subtype mediates sedation includes the fact that the non-BZD hypnotic Zolpidem (an 
imidazopyridine which nevertheless binds to the BZD recognition site) has higher affinity for α1-
GABAARs compared to other subtypes25 and that mice genetically modified to render their α1-
GABAARs insensitive to BZDs  show a much reduced sensitivity to the sedative effects of diazepam.26 
Similarly, it has been demonstrated that the  α2- and/or α3-GABAAR subtypes mediate anxiolysis27,28 
while the preferential expression of α5-GABAARs in the hippocampus29 and the improved cognitive 
performance in mice with reduced α5-GABAAR expression30 support the role of this subtype in 
cognition. These data have therefore formed the basis of hypotheses that PAMs that selectively 
modulate α2/α3-GABAARs should be non-sedating anxiolytics, possibly with a reduced tolerance and 
dependence liability,31 whereas α5-GABAAR NAMs would enhance cognitive performance but without 
the anxiogenic and proconvulsant liabilities associated with non-selective NAMs, such as FG7142.32 
More recently, data has emerged suggesting that α5-GABAAR PAMs might increase GABA-mediated 
inhibition and therefore reduce hippocampal activity in disorders such as schizophrenia that are 
associated with hippocampal hyperactivity.33 
GABAAR subtype selectivity may be achieved in one of two ways: i) subtype-selective affinity, 
in which a compound binds with higher affinity for a particular subtype(s) relative to others but has 
equivalent efficacy at each subtype, albeit that the functional affinity (EC50 values) reflect the binding 
affinity; ii) subtype-selective efficacy, in which a compound binds with equivalent affinity for each of 
the four (i.e., α1, α2-, α3- and α5-containing) GABAAR subtypes but only has functional effects at the 
subtype(s) of interest with no effects being observed at the other subtypes (at which the compound is a 
silent binder and behaves as an antagonist like flumazenil). In the present article, we will summarize 
key aspects of representative examples of compounds with various selectivity profiles, being either 
efficacy-selective, affinity-selective or a combination of the two, highlighting in particular, those α2/α3-
GABAAR PAMs and α5-GABAAR NAMs that have progressed into clinical studies over the last decade 
or so. What emerges clearly is that subtype-selective GABAAR modulators have preclinical and clinical 
pharmacological profiles that are very different from the non-selective modulators, whether they be 
PAMs or NAMs. However, and aside from the general issues (such as preclinical toxicology and clinical 
pharmacokinetics and tolerability) that can halt the clinical development of any particular drug, there 
remains the challenge of selecting the correct dose for the right patient population but even in these 
areas lessons are being learned and progress is being made. 
  
2. α2/α3-GABAAR PAMs 
2.1   Background and Context. Although BZDs are effective anxiolytics in the treatment of GAD, 
around 50% of patients report a significant degree of sedation which increases the risk of accidents34,35 
as well as falls, which are of particular concern in the elderly.36,37 Hence, there has long been a search 
for a non-sedating anxiolytic (“Valium without the sedation”) which has been described as a Holy Grail 
of psychopharmacology.38 With the dissection of the pharmacological mechanism of BZDs, the 
potential of an α2/α3-GABAAR PAM to be anxiolytic in GAD yet devoid of sedative side effects 
became apparent. However, the medicinal chemistry challenge was how this might be achieved. Initial 
attempts to achieve significantly (>10-fold) higher affinity for α2- and α3- versus α1-GABAARs proved 
unsuccessful, largely due to similarity of the BZD binding site at these different subtypes.39  
 
 
Figure 3. Structures and approximate chronological sequence of representative α2/α3-GABAAR 
functionally-selective agents. Compounds 1-8 are representatives of different classes of GABAAR 
PAMs, starting with the first prototypic compound L-838417 (1) through to the most recently-described 
clinical candidate PF-06372865 (8, now known as CVL-865). 
In contrast, the subtype-selective efficacy approach proved very fruitful with the identification 
of the prototypic α2/α3-GABAAR PAM L-83841740 (1, Figure 3) being followed by a variety of other 
compounds all of which have PAM activity at the α2- and α3-containing subtypes but have lower 
efficacy or are largely functionally silent (i.e., are antagonists) at α1-GABAARs (see Table 1 and Figure 
3). Of these compounds, several have progressed into clinical studies and been evaluated either in GAD 
(TPA023 and AZD7325, Figure 2) or in other indications that can be explored once the sedative effects 
associated with non-selective BZDs have been “dialed-out”. For example, PF-06372865 (now CVL-
865, 8, Figure 3) has been evaluated for efficacy against lower back pain41 and photosensitive epilepsy.42  
 
Table 1. Summary of the in vitro properties representative α2/α3-GABAAR PAMs 
Compound Structure 
Ki (nM)  Relative Efficacya 
α1 α2 α3 α5  α1 α 2 α3 α5 
Diazepam20 Benzodiazepine 16 17 17 15  1.0 1.0 1.0 1.0 
PF-06372865b Imidazopyridazine 0.18 2.92 1.06 18.0  0.11 0.35 0.49 0.70 
L-838417 
Triazolopyridazine 
0.79 0.67 0.67 2.25  0.02 0.43 0.43 0.39 
MRK-409 0.22 0.40 0.21 0.23  0.18 0.23 0.45 0.18 
TPA023 0.27 0.31 0.19 0.41  0.00 0.11 0.21 0.05 
TPA023B Imidazotriazine 0.73 2.0 1.8 1.1  0.03 0.38 0.50 0.37 
AZD7325 
Cinnoline 
0.5 0.3 1.3 230  -0.01 0.19 0.17 0.11 
AZD6280 0.5 5.0 31 1680  0.08 0.32 0.34 0.07 
NS11394 
Benzimidazole 
0.41 0.84 0.50 0.12  0.08 0.26 0.52 0.78 
NS16085 NRc  -0.10d 0.27 0.47 0.05 




300 160 527 82  0.27 0.52 0.36 0.23 
KRM-II-81e 489 118  205 NR  0.35 0.66 0.77 NR 
MP-III-024 e NR ~1,000 ~1,000 NR  25% 140% 129% 11% 
a Relative efficacy is the ability of a compound to increase the current produced by a submaximal (for 
example, an EC3-5 or an EC20) concentration of GABA relative to the potentiation observed for a non-
selective BZD such as diazepam or chlordiazepoxide. However, in the case of MP-III-024 values are 
expressed as the % potentiation of a GABA EC3 concentration. 
b Compounds in bold are those which 
progressed into clinical studies. c NR: not reported. d Negative relative efficacy values denote a NAM 
effect. e Affinity values are the functional affinity expressed as EC50, which in the case of MP-III-024 
were estimated by eye.  
 
2.2   The imidazopyridazine PF-06372865 (now CVL-865). Based upon similarity searches and the 
molecular overlaying of known GABAAR PAMs to establish a pharmacophore model, the Neusentis 
(Pfizer) group screened their in-house chemical collection to identify three general series with different 
heterocyclic cores (Series 1-3, Figure 4). The imidazopyridazine series (Series 2) was selected as the 
preferred chemotype based on an analysis of the affinity, functional selectivity, microsomal turnover 
and CNS penetration (estimated from an MDCK cell efflux assay).43  
 
Figure 4. General structures of the 3 series identified by screening for novel α2/α3-GABAARs PAM, 
with further optimization within Series 2 leading to imidazopyridazine PF-06372865 (8). aHLM Clint 
(μL min−1 mg−1) in vitro human microsomal stability measurement. bMDR er: efflux ratio of test 
compound at 2 μM across confluent monolayers from MDR1-transfected MDCK cells. 
A similar analysis was conducted on the direct- and ether-linked subseries within the 
imidazopyridazine chemotype and from this, the direct-linked scaffold was predicted to be far more 
likely to produce a compound with the desired functional selectivity.44 In this subseries, two preclinical 
lead compounds were identified, from which PF-06372865 (now known as CVL-865, 8, Figures 3 and 
4) was selected as the clinical candidate.44 PF-06372865 has 6-100-fold higher affinity for α1- relative 
to α2-, α3- or α5-GABAARs (Table 1) and is, as expected, devoid of affinity for α4- and α6-GABAARs.45 
Despite the higher affinity for the α1 subtype, PF-06372865 only very modest efficacy at this subtype 
(relative efficacy = 0.11), with efficacy at the α2-, α3- and α5-GABAAR subtypes being much higher 
(respective relative efficacy values of 0.35, 0.49 and 0.70). Although efficacy at the α5 subtype is higher 
than at α2- and α3-GABAARs, the lower affinity of PF-06372865 for α5-GABAARs combined with the 
lower expression of this subtype within the brain mean that most of the in vivo pharmacological effects 
of PF-06372865 are likely mediated by α2- and/or α3-GABAARs. 
PF-06372865 demonstrated excellent in vivo occupancy with the dose required to occupancy 
50% of rat brain GABAARs (the Occ50) varying from 0.3-1.0 mg/kg p.o., depending on brain region.45 
Implanted telemetry transmitters were used to show a dose-dependent increase in quantitative EEG 
(qEEG) beta frequency45 that was comparable to the α2/α3-GABAAR PAM L-838417.46,47 PF-
06372865 was anxiolytic in the elevated plus maze, analgesic in the chronic constriction injury model 
and was anticonvulsant in the mouse PTZ seizure and rat amygdala kindling models.44 In addition, PF-
06372865 dose-dependently reduced the number of spike-and-wave discharges in the genetic absence 
epilepsy rats from Strasbourg (GAERS).48 The rat half-life of 5.5 h for PF-06372865 translated into a 
half-life in man of 6.0-8.9 h over a dose range of 0.04 to 100 mg in an oral suspension.45 Doses of 10 
and 65 mg gave whole brain GABAAR occupancy of 69 and 89% in a [11C]flumazenil PET study and 
there were dose-dependent effects on a number of pharmacodynamic parameters, including saccadic 
peak velocity, qEEG and a slight increase in body-sway, with the latter possibly being related to 
sedation and/or myorelaxation that was α1-GABAAR-mediated.45  
While a Phase 2 study in GAD was terminated early for business reasons with only 90 of the 
planned 384 subjects having been enrolled into the study,49 PF-06372865 demonstrated robust efficacy 
in a small study of photosensitive epilepsy patients.42 Following single doses of drug (17.5 and 52.5 
mg), participants had a reduction in the response to intermittent photic stimulation that was comparable 
to lorazepam, which served as the active comparator. Accordingly, PF-063728675 was licensed to 
Cerevel Therapeutics and is now being developed as an antiepileptic drug.   
In healthy subjects, single 15 mg or 65 mg doses of PF-06372865 had an analgesic effect on 
pressure pain and the cold pressor task as judged by an increase in the pain tolerance threshold in the 
absence of any signs of sedation50. However, PF-06372865 did not demonstrate efficacy in a Phase 2 
study of chronic low back pain,41 although as noted by the authors, the doses selected (2.5-7.5 mg) may 
not have been sufficient to achieve adequate GABAAR occupancy.  
 
2.3 The 1,2,4-triazolo[4,3-b]pyridazine series: MRK-409 and TPA023. The 
triazolopyridazine series developed by Merck resulted not only in the identification of the prototypic 
pharmacological tool compound L-83841740 (1, Figure 3) but also the clinical candidates MRK-409 
and TPA023 (2 and 3, respectively, Figures 3 and 5). The starting point for this series was compound 9 
(in which the triazolopyridazine core is highlighted in blue in Figure 5), which demonstrated a modest 
(<5-fold) α2/α3-GABAAR binding selectivity and was used as a hit for further optimization.51 The 
replacement of the 2-pyridyl moiety with a 1,2,4-alkyltriazole (10, Figure 5) was accompanied by a 
shift from affinity- to efficacy-selective compounds, and the replacement of the bicyclic scaffold with 
either a cyclobutyl or a t-butyl group producing a significant reduction of efficacy at α1-GABAARs. 
Within the t-butyl subseries, compound 12 (Figure 5) had the desired α2/α3-GABAAR PAM and α1 
antagonist efficacy profile but the unsubstituted phenyl group of this compound resulted in a high in 
vitro metabolism as measured in a microsome assay.  
This in vitro metabolic liability observed in 12 was addressed by replacing the phenyl with a 
2,5-difluorophenyl group and the resulting compound L-838417 was an antagonist at α1-GABAARs 
and became the prototypic α2/α3-GABAAR efficacy-selective pharmacological tool PAM. Hence, L-
838417 had similar binding affinity across the four GABAAR subtypes and partial PAM efficacy at α2, 
α3 and α5 subtypes (with relative efficacy values ranging from 0.39-0.43; Table 1) but negligible 
efficacy at the α1 subtype.40 This compound was characterized in vivo and demonstrated anxiolytic-like 
activity with no impairment in motor performance in rats and primates.39,52 Although this compound 
was relatively stable in an in vitro metabolism assay, it had poor in vivo pharmacokinetics which 
prevented its further preclinical development.53 Nevertheless, this compound was important in 




Figure 5. The discovery of MRK-409 (2) and TPA023 (3). The efficacy values are in comparison with 
the non-selective BZD chlordiazepoxide (which, by definition, has a relative efficacy at each subtype 
of 1.0). For clarity, efficacy values for α2-GABAARs (which generally closely track values at the α3 
subtype) and α5-GABAARs have been omitted. 
aant. = antagonist (i.e., relative efficacy ~0.0). 
 
Within the cyclobutyl subseries, MRK-06739 (11, Figure 5) had higher efficacy at α2- and α3- 
compared to α1-GABAARs and proved to be a non-sedating anxiolytic in preclinical species. On the 
basis of these data, MRK-067 was selected as a preclinical candidate but further development was halted 
due to the demonstration of covalent binding due to CYP1A2-mediated metabolism on the unsubstituted 
phenyl ring; an issue that was addressed by the introduction of a 2,6-difluorophenyl group into MRK-
409. This compound had equal affinity for all four (α1-, α2-, α3- and α5-containing) GABAAR subtypes, 
with Ki values ranging from 0.21 to 0.40 nM. The efficacy was greater at α3- versus α1-GABAARs 
although, and as with MRK-067, there remained a modest degree of potentiation of GABA currents at 
this latter subtype (relative efficacy = 0.18) which although insufficient to cause sedation in preclinical 
species, ultimately resulted in sedation in man (see below). 
MRK-409 readily entered the rat brain with the dose required for 50% in vivo GABAAR 
occupancy (Occ50) being 2.2 mg/kg p.o. and it was anxiolytic in unconditioned (rat elevated plus maze) 
and conditioned (rat fear-potentiated startle and conditioned suppression of drinking, and squirrel 
monkey conditioned emotional response) preclinical models of anxiety.54 The compound did not cause 
sedation in the mouse rotarod or squirrel monkey lever pressing assays and therefore appeared to be 
non-sedating. On the basis of these data, MRK-409 (also described as MK-0343) progressed into the 
clinic where in single-ascending dose studies, a 2 mg dose unexpectedly produced marked sedation and 
the maximum tolerated dose was defined as 1 mg, at which dose [11C]flumazenil positron emission 
tomography (PET) studies showed GABAAR occupancy to be below the limits of detection (<10%).55  
As a result of these unexpected data, further development of MRK-409 as a non-sedating anxiolytic 
was halted. The failure of preclinical species to predict the sedative effects of MRK-409 in man was 
also experienced with the non-selective partial PAM bretazenil, which exhibited an anxio-selective 
profile in preclinical models but induced sedation in healthy volunteers.56 It was assumed that - and for 
whatever reason - humans are particularly sensitive to even modest efficacy at α1-GABAARs and that 
the relative efficacy of 0.18 for MRK-409 at this subtype was nevertheless still sufficient to produce 
pronounced sedation in man. This therefore defined the requirement for subsequent compounds to have 
zero intrinsic efficacy (i.e., be an antagonist) at α1-GABAARs.  
Following the unexpected failure in the clinic of MRK-409, attention turned back to the t-butyl 
subseries and the poor in vivo pharmacokinetics of L-838417 was addressed primarily by the 
replacement of the 2-methyl-1,2,4-triazole with the ethyl analogue which resulted in the identification 
of TPA02351,57 (also known as MK-0777). This compound has equivalent affinity (ranging from 0.19 
to 0.41 nM) for the α1-, α2-, α3- and α5-GABAAR subtypes and has efficacy at α2- and α3-GABAARs, 
with respective relative efficacy values of 0.11 and 0.21, but 0.0 efficacy at the α1 subtype (Table 1). 
Like MRK-409, TPA023 gave excellent target engagement in rats with an Occ50 of 0.42 mg/kg p.o. and 
a plasma concentration required to give 50% occupancy (plasma EC50) of 25 ng/mL.58 TPA023 
demonstrated anxiolytic-like effects but no sedative action in rats and primates59,60 and the compound 
progressed into preclinical toxicology studies, during which cataract formation in dogs was observed in 
high-dose, long-term studies (3 mo. at 100 mg/kg p.o. or 1 y. at 30 mg/kg p.o.). However, since there 
was a very large safety margin, the compound progressed into the clinic and in Phase 1 healthy 
volunteers, TPA023 was generally well-tolerated with the maximum tolerated doses being defined by 
adverse events such as light headedness, dizziness and drowsiness. Single doses of 2 mg TPA023 
produced ≥50% GABAAR occupancy in a [11C]flumazenil PET study with no signs of sedation and 
plasma concentrations of 9 ng/mL corresponding to 50% occupancy.58 The pharmacodynamic effects 
of TPA023 were compared to lorazepam in a healthy male volunteers,61 using saccadic peak velocity 
(SPV) or body sway as markers of GABAergic pharmacology.62 TPA023 produced a significant dose-
dependent reduction in SPV but no effects were observed on body sway or either a visual analogue 
scales (VAS) of alertness or a variety of cognitive function tests. In contrast, while lorazepam likewise 
increased the SPV, it also produced a marked increase in body sway and impaired alertness and 
cognitive function.61 Next, three Phase 2a studies were initiated in GAD, with each study being a two-
arm (placebo versus TPA023), 125-patient per arm double-blind, randomized controlled trial, using the 
Hamilton Anxiety (HAM-A) rating scale as the primary end point. However, shortly after each of the 
trials had commenced, cataract formation was reported in high dose, long-term (2-year) rodent 
carcinogenicity studies. Despite the fact that the therapeutic margin had not decreased and was still 
defined by the dog studies conducted prior to the commencement of the Phase 1 studies, the decision 
was nevertheless taken to halt development of TPA023. A post-hoc analysis of the combined data from 
the three terminated studies showed a significantly greater decrease in the HAM-A scores of TPA023- 
versus placebo-treated patients, consistent with an anxiolytic-like effect of the compound in man.57 
Although development of TPA023 in GAD was stopped, the compound was thereafter evaluated in an 
exploratory study in schizophrenia, in which the drug showed a trend towards improving cognitive 
symptoms63 that were not confirmed in subsequent a larger study.64 In addition, TPA023 had no effect 
in essential tremor.65 
 
2.4   The imidazotriazine compound TPA023B. Based upon the benzimidazole starting point NS-
2710,66 the imidazotriazine TPA023B (4, Figures 3 and 6) was identified by a sequential modification 
of the benzimidazole core. Hence, the nitrogen atoms in the benzimidazole core were rearranged to 
produce the imidazopyridine series (typified by compound 14, Figure 6) which had a suitable in vitro 
profile but generally poor rat pharmacokinetics. This issue was addressed by introducing an 
imidazopyrimidine core (15, Figure 6) which gave good rat but generally poor dog pharmacokinetics. 
Notable exceptions within this series were MRK-623 and MRK-898 which progressed into preclinical 
development pending the outcome of the clinical studies with the lead and back-up compound (TPA023 
and TPA023B, respectively). The addition of a further nitrogen into the imidazopyrimidine core 
resulted in the imidazotriazine series (16, Figure 6) which resulted in good rat and dog pharmacokinetics 
with further optimization resulting in the identification of TPA023B.67 Interestingly, the structure-
activity relationship (SAR) could be largely retained across series, despite their different core structures. 
 
 
Figure 6. The NS-2710 core modifications leading to the discovery of TPA023B. The sequential 
addition of nitrogen atoms to the core addressed poor rat and then dog in vivo pharmacokinetics. 
 
 
As with the triazolopyridazine clinical candidates MRK-409 and TPA023, TPA023B had 
similar affinity for the four GABAAR subtypes (Ki values ranging from 0.7 to 2.0 nM, Table 1) and 
while the respective α2- and α3-GABAAR relative efficacy values of 0.38 and 0.50 were higher than 
the corresponding values of 0.11 and 0.21 for TPA023, it was nevertheless possible to retain the lack 
of potentiation at the α1 subtype. TPA023B was particularly potent at occupying rat brain GABAAR 
receptors with an Occ50 of 0.09 mg/kg p.o. and a plasma EC50 of 19 ng/mL and was a non-sedating 
anxiolytic in rodents and primates.68 In man, the compound was well tolerated with the maximum 
tolerated single dose in healthy young men was defined as 2 mg based upon observations of fatigue, 
tiredness and somnolence/drowsiness at a dose of 3 mg. In a [11C]flumazenil PET study, single doses 
of 1.5 mg of TPA023B did not produce sedation at cortical GABAARs occupancies of 52% and 46% 
measured 5 and 24 h after dosing, respectively, with the plasma EC50 value being 5.8 ng/mL.69 
Therefore, and consistent with TPA023, TPA023B did not produced a marked sedation even at 
relatively high levels of occupancy (roughly 50%). However, this compound did not advance into 
further clinical trials as a consequence of the project being terminated for business reasons. 
Nevertheless, TPA023B continues to be a very useful preclinical tool compound and has been used, for 
example, to define the role of α2/α3-GABAAR PAMs in reducing itch.70  
 
2.5 Cinnolines AZD7325 and AZD6280.   Initial studies examining the GABAAR modulatory effects 
of cinnoline- (the prototypic example of which is ICI 198,256)71 and related quinoline-based 
compounds were halted due to the low bioavailability of these molecules, along with their potential to 
form reactive metabolites.72. However, these compounds were chosen by AstraZeneca as good starting 
points for their renewed interest in developing subtype-selective GABAAR modulators.73,72 The 
exemplars of the cinnoline series and related quinoline structures (17 and 18, Figure 7) had high efficacy 
for α1-GABAARs while at the same time being metabolically unstable. 
Changes to the cinnoline series were focused around the aryl group in the 8 position and the amidic 
portion. A few aliphatic chains were tolerated in the amide functionality, mainly short linear tethers and 
their equivalent carbocycles, with the n-propyl sequence giving the best results in terms of α2- vs α1-
GABAAR functional selectivity. With the n-propylamide in place, the 8-aryl cinnolines were of 
particular interest since they retained α2-GABAAR binding affinity but depending upon the substituents 
on the aromatic ring, a range of efficacies at the α1 subtype were observed. Nitrogen-containing 
heterocyclic replacements of the phenyl group did not confer any advantage and therefore the 2-fluoro-
6-methoxypenyl and 2,5-dimethoxyphenyl analogues, AZD7325 and AZD6280 respectively (6 and 20, 
Figure 7), were selected for clinical development. 
 
 
Figure 7. Structures of the quinoline- (17) and cinnoline-based (18) AZ starting points and general 
structure of the cinnoline-based new compounds (19). The SAR around this nucleus led to the 
identification of the clinical candidates AZD7325 and AZD6280 (6 and 20, respectively). 
  
AZD7325 has high affinity for α1-, α2- and α3-GABAARs (Ki of 0.5, 0.3 and 1.3 nM, 
respectively) but (and like PF-06372865) affinity was lower at α5-GABAARs (Ki = 230 nM).72,47 It 
displayed no and low efficacy at α1- and α5-containing GABAARs, respectively and partial efficacy at 
the α2- and α3-subtypes. AZD7325 gave good rat brain GABAAR occupancy with an Occ50 in the region 
of 1-2 µmol/kg s.c. as well as a robust anxiolytic effect in a punished responding task. There was 
sedation in the unpunished responding assay and a significant, dose-dependent increase in the EEG β 
and γ spectral power band.47 AZD7325 was also anxiolytic in a mouse model in which a mutation in 
the collybistin-binding region of the α2 subunit produces an anxiogenic phenotype74 and it also protects 
against seizures in a mouse model of Dravet syndrome75 as well as attenuating the impairment of 
prepulse inhibition and reversing dendritic abnormalities produced by siRNA knockdown of DISC1.76  
Preclinical in vitro studies highlighted the potential for AZD7325 to be an inducer of CYP3A4 
and CYP1A2. However, in man co-administration studies of AZD7325 with the CYP3A4 substrate 
midazolam and the CYP1A2 substrate caffeine showed that there was a limited potential for AZD7325-
mediated drug-drug interactions at clinically-relevant doses.77 In a single ascending dose study, 0.2 to 
100 mg were well tolerated with a dose of 20 mg corresponding to an average occupancy in a 
[11C]flumazenil PET study  of 83% in the occipital cortex and the cerebellum.78 
Table 2. Summary of the in-vitro affinity/efficacy of the cinnoline-based series 
8-aryl substitutionsa  N-alkyl chainsb 
 
α2 pKi 
α1 Rel. Eff.c 




α1 Rel. Eff.c 









































aSAR around 8-aryl and heterocycle substitutions of cinnoline N-propylamides. bSAR of amide 
substitutions of 8-(2,5-dimethoxyphenyl)-cinnolines. c Efficacy is relative to the potentiation observed 
for the non-selective BZD diazepam. dNR: not reported.  
 
Doses of 2 and 10 mg AZD7325 were safe and well-tolerated in a pharmacodynamic study in 
healthy controls and although the 10 mg dose produced a reduction on delta (2-4 Hz) and theta (4-7.5 
Hz), the effects on a variety of other different pharmacodynamic markers was relatively modest.79 
AZD7325 was then evaluated in two, 4-week Phase 2a studies in GAD. In the first study 
(Clinicaltrials.gov identifier NCT00808249), AZD7325 was dosed at either 2 or 5 mg twice a day or 10 
mg once a day whereas in the second (NCT00807937) doses of 5 or 15 mg were administered twice a 
day. While neither study achieved its primary end-point (significantly greater change in the HAM-A 
rating scale relative to placebo), the placebo response rate was considered to be high and the 10 mg 
dose reduced other anxiety endpoints and the depression MADRS score.80 Moreover, both studies were 
confounded by a high rate of non-compliance (as defined by the absence of drug in plasma samples 
removed for pharmacokinetic analyses) and post-hoc analyses with data from non-compliant subjects 
removed demonstrated a clear anxiolytic-like effect (Dr. Alan Cross, personal communication). 
Although AstraZeneca terminated their internal efforts, AZD7325 has been made available to 
investigators as part of the AstraZeneca Open Innovation initiative and is currently under investigation 
in a small, 15-participant study of the effects of drug (5 or 15 mg twice a day for adults with fragile X 
syndrome (NCT03140813) as well as in a study in 100 adults with autism spectrum disorder 
(NCT03678129) in which single doses of 10 or 20 mg will be used to study the effects on brain 
neurochemistry and functional connectivity measured using magnetic resonance imaging. 
The second clinical candidate AZD628081 differed from AZD7325 in that although both 
compounds had a similar (0.5 nM) affinity at α1-GABAARs, AZD6280 has lower affinity for the α2-, 
α3- and α5-GABAAR subtypes but has greater intrinsic efficacy at the α2 and α3 subtypes compared to 
AZD7325 (Table 1). The lower affinity of AZD6280 is presumably in part responsible for its 
approximately 10-fold lower potency in a rat [3H]flumazenil occupancy assay relative to AZD732547 
as well as a human [11C]flumazenil PET study.78 Nevertheless, and presumably because of its greater 
intrinsic efficacy, 10 and 40 mg doses of AZD6280 were able to increase plasma prolactin levels in 
healthy male volunteers, as was a 2 mg dose of lorazepam whereas 2 and 10 mg doses of AZD7325 
were without effect.82 These same 10 and 40 mg doses of AZD6280 were tested in a variety of additional 
pharmacodynamic readouts and while the effects were generally not to the same extent as those seen 
with lorazepam, they were nevertheless more marked than observed with AZD7325.79,81 No further 
clinical studies for this compound have been reported.  
 
2.6 Benzimidazole NS11394 and related compounds. The Danish company NeuroSearch 
(subsequently renamed Aniona and then Saniona) have a long heritage in the field of benzimidazole-
based GABAAR PAMs typified by NS-2710 (13, Figures 6 and 8), NS11394 (5, Figure 3 and 8) and 
NS16085 (21, Figure 8). They have also described the clinical candidate NS11821, which although no 
structure has been publically disclosed is assumed to be of this same chemotype (Figure 8).83 
NS11394 has roughly equivalent, subnanomolar affinity (ranging from 0.1-0.8 nM, Table 1) for the 
different GABAAR subtypes and had relative efficacy values at the α1-, α2-, α3- and α5-subtypes of 
0.08, 0.26, 0.52 and 0.78, respectively. The maximal ED50 for occupying rat brain GABAARs was 0.69 
mg/kg p.o.83 and NS11394 was shown to be anxiolytic in different assays at doses ranging from 0.1 and 
0.3 mg/kg with only a slight degree of impairment on rotarod performance and locomotor activity at 
doses (≥60 mg/kg) that are >100-fold higher than anxiolytic doses.83 There is considerable evidence to 
suggest that α2/α3-GABAAR PAMs may exert analgesic effects in the spinal cord, probably related to 
the α2 subtype.84,85,86 In this regard, NS11394 has also been shown to be analgesic in a variety of 
inflammatory and neuropathic pain models.87 NS11394 unexpectedly also caused a worsening of 
symptoms in the dtsz mutant hamster model of dystonia,88 in contrast to clonazepam which demonstrated 
a marked beneficial effect and zolpidem which showed a modest improvement.89  
 
Figure 8. From NS-2710 to the optimized benzimidazole-based NS-compounds. Two-point 
modification in NS-2710 (characterized by a modest degree of 3 vs 1 selective efficacy) resulted in 
compound NS11394 (5), endowed with selectivity profile in the order of 5>3>2>1, and higher 
3-GABAARs efficacy. Further modification to the diaryl-system yielded NS16085 (21), exhibiting 
negligible activity at 5-GABAARs. SAR analysis around NS11821 (22) remains undisclosed. 
 
The analgesic efficacy of NS11394 can be attributed to the α2- and/or α3-GABAAR subtype(s) 
by comparison with NS16085. Hence, this latter compound has α2/α3-GABAAR efficacy comparable 
to NS11394 but is devoid of effects at α5-GABAARs (relative efficacy = 0.05 vs 0.78 for NS11394). 
Nevertheless, NS16085 retained analgesic efficacy, indicating that α5-GABAARs do not play a role in 
analgesia.90 
Although neither NS11394 nor NS16085 progressed into clinical development, the presumably 
structurally-related analogue, NS11821 was evaluated in man.91 NS11821 has high and relatively non-
selective affinity for the different GABAAR subtypes (Ki values ranging from 1.6-9.7 nM; Table 1), 
weak to moderate PAM efficacy at the α2, α3 and α5 subtypes (relative efficacy values of 0.17, 0.40 
and 0.41, respectively) but negligible effects at the α1 subtype (relative efficacy of 0.04). It 
demonstrated anxiolytic-like activity with a minimum effective dose of 3 mg/kg, without affecting 
rotarod performance.91 In a Phase 1 pharmacodynamic study, NS11821 was relatively safe and well-
tolerated with the highest dose tested (600 mg, corresponding to a Cmax of 1,430 ng/mL) producing 
nausea, vomiting, fatigue, dizziness and/or somnolence in ≥ 50% of six subjects. Lower single doses of 
NS11821 (i.e., 10, 30 and 75 mg) did not demonstrate and marked pharmacodynamic effects. However, 
the higher doses of 150, 300 and 600 mg all produced statistically significant effects on a variety of 
parameters, with effects on saccadic peak velocity being observed at the 300 and 600 mg doses. Most 
notably, the 600 mg dose showed impairments in alertness, was associated with feeling high 
impairments and altered the EEG beta bands of the power spectrum. The increase in the time taken to 
achieve peak plasma drug concentrations between the 15 mg and 600 mg doses (respective Tmax values 
of 0.5 and 4.0 h) suggested a complex absorption pattern that was thought to be associated with the low 
solubility of the compound.91 Accordingly, it was suggested that modifications in the formulation of 
NS11821 might result in improved bioavailability and dose-proportionality. 
 
2.7 Imidazobenzodiazepines. Based upon an imidazobenzodiazepine core typified by flumazenil (23, 
Figure 9), bretazenil and imidazenil, Cook and colleagues at the University of Wisconsin described a 
compound, HZ-166 (26, Figure 9) that had relatively low and non-selective affinity for the different 
GABAAR subtypes (Ki values ranging from 82-527 nM) and produced greater potentiation at α2- and 
α3- compared to α1- and α5-GABAARs.92 However, when the values are expressed relative to the 
potentiation produced by diazepam, HZ-166 was relatively non-selective (Table 1).93 Nevertheless, 
HZ166 was not only anticonvulsant but it also was a non-sedating anxiolytic in rhesus monkeys.92,93 
The related compounds XHe-II-053 and JY-XHe-053 (24 and 25, Figure 9) had slightly or markedly 
higher GABAAR affinity, respectively, than HZ-166 but again neither had subtype-selective efficacy93 
(Table 1) and interestingly, JY-XHe-053 was not anxiolytic in the elevated plus maze.94 Replacement 
of the ethyl ester of HZ-166 with a methyl ester resulted in a compound MP-III-024 (27, Figure 9) 
which had an improved in vitro metabolic stability and demonstrates analgesic effects but no sedation 
in mice.95  
 
Figure 9. Examples of imidazobenzodiazepines α2/α3-GABAAR PAMs related to the prototypic non-
selective antagonist flumazenil. The ester-containing analogues (24-27) have poor metabolic stability 
and the ester to oxazole/oxadiazole bioisosteric replacement afforded a new series of compounds (7, 
28-31) with optimized profiles and anxiolytic, analgesic, anticonvulsant and antidepressant activities. 
 
The ester-containing compound XHe-II-053 was reported to have been progressed into Phase 
1 clinical trials by Bristol-Myers Squibb. However, the compound was rapidly transformed into the 
metabolite XHe-II-053-acid by liver enzymes,96 resulting in the search for more metabolically-stable 
analogues. Since the ester group in these first generation imidazobenzodiazepines is a metabolic 
liability, compounds were synthesized in which either an oxazole or (alkyl)oxadiazole (28 and 29, 
Figure 9) were used as a more metabolically-stable ester bioisostere.96,97,98 The oxazoles subseries 
includes the compounds KRM-II-82, KRM-II-18B and KRM-II-81 (30, 31 and 7, Figure 9), of which 
the latter is the best described.97 Hence, KRM-II-81 has a EC50 and relative efficacy at the 1-, 2- and 
3-subtypes in the range of 118-489 nM and 0.35-0.77, respectively, with negligible efficacy at 5-
GABAAR efficacy being detected97 (Table 1). This compound demonstrates anxiolytic, analgesic and 
anticonvulsant effects.97,98,99,100 As regards the compounds with an oxadiazole replacement of the ester 
group, then in vitro metabolic stability is improved96 and a representative compound from this class, 
MP-III-80 (28, Figure 9), was shown to have antidepressant-like activity.101 Since these compounds all 
possess varying degrees of efficacy at α1-GABAARs, they are probably best described as being α2/α3-
GABAAR preferring to distinguish them from compounds that lack any efficacy at the α1 subtype which 
are therefore α2/α3-GABAAR selective. 
 
3. α5-GABAAR NAMs 
3.1 Background and Context. As above-mentioned, α5-GABAARs are preferentially expressed within 
the hippocampus29 which has a well-established role in learning and memory, resulting in the hypothesis 
that α5-GABAAR NAMs should enhance cognition.102 However, an increased activity in the 
hippocampal formation in the aging brain,103 schizophrenia patients33 or neuropsychiatric disorders with 
cognitive deficits,104 has recently highlighted the therapeutic potential of α5-GABAAR PAMs105,106 
which will be addressed separately below. While the BZD binding sites at α1-, α2-, and α3-GABAARs 
have a high degree of similarity, thus making it difficult to find compounds with binding affinities that 
differentiate between these subtypes, α5 GABAARs appear to have an allosteric site that is more distinct 
from the other subtypes.107 Accordingly, the identification of ligands with α5-GABAAR-selective 
affinity appears to be more achievable compared to α2/α3-GABAAR binding-selective modulators. For 
example, the NAM L-655708 (33, Figure 10)108 has 50-100-fold higher affinity for α5- versus α1-, α2- 
and α3-GABAARs whereas conversely zolpidem has moderate to high affinity for α1-, α2- and α3-
GABAARs (ranging from 17-360 nM) but no affinity for the α5 subtype.20  
 
Figure 10. Structures and chronological sequence of the description of various α5-GABAAR NAMs. 
Compounds 32-40 are representatives of different classes of NAMs, starting with the 
imidazobenzodiazepines and moving to the recently-described compounds Basmisanil (RG1662; 39) 
and ONO-8590580 (40). Of these compounds, α5IA (35), MRK-016 (37) Basmisanil (39) have all 
progressed into clinical studies. 
 
 
Table 3. Summary of the in vitro properties of α5-GABAAR NAMs 
Compound Structure 
Ki (nM)  Efficacya 
α1 α2 α3 α5  α1 α 2 α3 α5 
RO4882224  Imidazotriazolo- 
benzodiazepine 
15 24 14 2.0  -3% -9% -11% -40% 
RO4938581 174 185 80 4.6  -3% -4% 2% -35% 
Basmisanil Isoxazole-Pyridine 985 502 489 4.7  -4% -6% -2% -39% 
α5IAb Triazolopyridazine 0.88 0.58 0.61 0.66  -0.25 0.10 -0.11 -0.70 




362 180 328 6  20% 15% 45% -20% 
ONO-8590580 Benzimidazole 140 32 24 7.9  ~0% ~0% ~0% -44% 
 
a Efficacy is expressed either as a % reduction in the GABA-induced current or is expressed relative to 
the reduction in GABA current produced by NAM, the prototypic non-selective GABAAR NAM. 
bCompounds in bold are those which progressed into clinical studies. 
 
 
3.2 Roche compounds. The imidazotriazolo-benzodiazepines RO4882224 (38, Figure 10) and 
RO4938581 were identified following optimization of hits from a screening campaign.109,110 
RO4882224 has a moderate (7-12-fold) and RO4938581 an appreciable (17-40-fold) α5- versus α1-, 
α2- or α3-GABAAR binding selectivity. In addition, both compounds also had a marked α5-GABAAR 
NAM efficacy selectivity (Table 3), making them α5 binding and efficacy selective. Both compounds 
attenuated a scopolamine-induced deficit in cognitive performance in the rat delayed matching to 
position test110 and RO4938581 improved executive function in monkeys110 and rescued behavioral, 
anatomical and biochemical abnormalities in a mouse model of Down syndrome (DS).111,112 Although 
both RO4882224 and RO4938581 were selected as clinical candidates for further development,109 no 
further details regarding their preclinical or clinical development have been reported and it could have 
been presumably halted due to preclinical hepatotoxicity issues associated with these compounds. 
An isoxazole-pyridine series was optimized to produce the clinical candidate Basmisanil 
(RG1662, 39, Figure 10). Although no peer-reviewed publication has appeared describing this 
compound, it is described in the patent US8835425(B2) as compound R1.113 Hence, Basmisanil not 
only has 100-200-fold α5- versus α1- α2- and α3-GABAAR binding selectivity (Table 3), but it is also 
has α5-selective NAM efficacy such that, and like RO4882224 and RO4938581, it also has α5 subtype 
binding and efficacy selectivity. In a [11C]RO15-4513 PET study, doses of 20-1000 mg RG1662 
produced a dose- and exposure-proportional reduction in radiotracer uptake and a maximum receptor 
occupancy of around 80%, with the plasma drug concentration required to produce 50% occupancy 
being in the region of 750 ng/mL.114 Basmisanil was described as attenuating the deficits in long-term 
potentiation and performance in the Morris water maze seen in Ts65Dn mice113 and presumably on this 
basis was progressed into Phase 2 clinical studies in adolescents and adults with DS. However, RG1662 
did not show any efficacy in the cognitive or behavioral primary endpoints and the compound is now 
being assessed for its effects on cognitive performance in schizophrenia (NCT02953639). 
 
3.3 Merck compounds. The lead α5-GABAAR NAM compound described by the Merck group was 
the triazolophthalazine α5IA (35, Figures 10 and 11).115 This compound shared a common ancestry with 
the α2/α3-GABAAR PAM TPA023 and optimization of the parent compound (Figure 11) resulted in 
the identification of α5IA. It showed equivalent subnanomolar affinity across the different GABAAR 
subtypes (ranging from 0.58-0.88 nM; Table 3) but had much higher NAM efficacy at the α5 compared 
to the α1-, α2- and α3-GABAAR subtypes (Table 3), displaying a relative efficacy of -0.70 compared to 
the prototypic non-selective GABAAR NAM DMCM. α5IA also demonstrated good in vivo GABAAR 
occupancy in mice and rats with Occ50 values of 0.12 and 0.25 mg/kg p.o. in mice and rats,115 
respectively, as well as in primates.116  
 
  
Figure 11. The SAR analysis leading to the PAM TPA023 (3) and to the NAM α5IA (35), starting from 
the common ancestry triazolopyridazine analogue (9). These compounds illustrate the concept that 
different selectivity profiles (α2/α3-GABAAR PAMs or α5-GABAAR NAMs) can be developed from a 
common chemical starting point.  
 
It improved performance in a delayed-matching-to-place version of the Morris water maze,117 and had 
no proconvulsant effect in the pentylenetetrazole assay and nor anxiogenic effect in the rat elevated plus 
maze assay. In man, α5IA was safe and well tolerated118 and demonstrated good levels of target 
engagement in a [11C]flumazenil PET study with a single 2 mg dose producing GABAAR occupancy in 
the region of 50% and a plasma EC50 of 10 ng/mL.119 However, further development of this compound 
was halted due to the occurrence of renal toxicity in preclinical species. The toxicity was caused by the 
deposition of crystals of the insoluble, hydroxymethyl isoxazole metabolite of α5IA that made it 
unsuitable for long-term dosing in man.118 Nevertheless, the compound was suitable for short-term 
dosing and in an experimental medicine paradigm in healthy volunteers in which an impairment in list 
recall was induced by alcohol consumption, α5IA showed a significant improvement in list recall 
compared to placebo-treated subjects.120 
 
 
Figure 12. The SAR study around compound 9 leading to α5AI and MRK-016. P1: replacement of the 
phenyl group at C-3 position with oxadiazole and isoxazole gave lead intermediates for binding and 
efficacy selectivity, respectively; P2: replacement of the [2.2.2]-bicyclic ring system with a benzo-fused 
ring addressed metabolic stability issues but did not improve oral bioavailability. P3: initial substitution 
of 6-methylpyridin-2-yl group with a dimethyl pyridyl moiety in the [2.2.2]-bicyclic ring system gave 
the maximum binding selectivity in the series. The following combination of 1-methyl-1,2,3-triazol-4-
yl with the benzo-fused ring led to the identification of α5AI (35, Figures 9 and 10). P4: different 
heterocyclic cores have been explored. By merging the isoxazole and triazole groups in a 
pyrazolotriazine core with a tert-butyl moiety, MRK-016 (37, Figure 9) was identified. 
 
By replacing the triazolophthalazine core of α5IA with a pyrazolotriazine while retaining the 
isoxazole and triazole groups and replacing the bicyclic ring system in α5IA with a tert-butyl group 
(Figure 12), the back-up compound MRK-016 (37, Figure 10) was identified.121  This molecule has high 
and equivalent affinity across the GABAAR subtypes (0.77-1.4 nM), with α5-GABAAR selective 
efficacy profile similar to that of α5IA except that MRK-016 has great NAM activity at the α5 subtype 
(relative efficacy = -0.96). MRK-016 gave good receptor occupancy after oral dosing in rats, with the 
Occ50 being 0.39 mg/kg p.o. and a corresponding rat plasma EC50 value of 15 ng/mL. It was able to 
enhanced cognitive performance in the delayed matching-to-position version of the Morris water maze 
and was not proconvulsant or anxiogenic. MRK-016 has also been shown to protect against 
lipopolysaccharide-induced deficits in memory acquisition and consolidation and restore the behavioral 
expression of fear in lipopolysaccharide-treated animals, an effect that may be attributed to increased 
brain-derived neurotrophic factor mRNA expression.122,123 Finally, MRK-016 has antidepressant-like 
activity in a variety of preclinical assays.124,125,126 
Although MRK-016 had a short half-life in preclinical species, it had a lower rate of in vitro 
turnover in human hepatocytes and this translated into a half-life in man of 3.5 h. Based on plasma drug 
concentrations and the occupancy EC50 value in rhesus monkey (21 ng/mL) the maximum tolerated 
dose of 5 mg in young healthy controls was estimated to correspond to 75% GABAAR occupancy.121 
However, MRK-016 studies in man were halted due to poor tolerability in the healthy elderly volunteers 
as well as variable pharmacokinetic,121 and based upon these data clinical development of this drug was 
terminated.  
 
3.4 Imidazobenzodiazpines. Based upon the structure of RO15-4513 (32, Figure 10), which has 10-
20-fold higher affinity for α5- versus α1-, α2- and α3-GABAARs, Cook and colleagues synthesized a 
series of α5 binding-selective compounds typified by RY-080 (34, Figure 10), but which also included 
RY-023, RY-024 and RY-079.127  This in turn led to the identification of PWZ-029128 (36, Figure 10) 
which has 30-60-fold binding selectivity for α5- versus α1-, α2 and α3-GABAARs (Table 3).128,129 This 
compound has a degree of PAM activity and the α1, α2 and α3 subtypes but modest NAM activity at 
α5-GABAARs128 such that it is best described as a low-efficacy α5-GABAAR NAM whereas RY-023, 
RY-024 and RY-080 are classified as high-efficacy α5-selective compounds130. Hence, RY-080 
attenuates GABA-induced currents at the α5 subtype by around 36% whereas the corresponding value 
for PWZ-029 was only 17%.131 The relatively weak α5-GABAAR NAM activity of PWZ-029 is 
reflected in the lower efficacy of this compound in the mouse forced-swim assay relative to RY-080.131 
PWZ-029 improved learning in a rat passive but not active avoidance task at a dose, 5 mg/kg i.p., that 
was just below those at which an impairment in locomotor activity was observed (10 and 20 mg/kg).128 
Despite its relatively weak α5-GABAAR NAM activity, PWZ-029 was nevertheless able to enhance 
performance in a rhesus monkey object retrieval task that was either “difficult” or in which performance 
was impaired by scopolamine.129 All these imidazobenzodiazepines appear to be preclinical tools with 
none having been described to date as having entered clinical or preclinical development.  
 
3.5 Other compounds. The benzimidazole ONO-8590580 (40, Figures 10 and 13) was recently 
described as an α5-GABAAR NAM.132 The affinity of this compound for the α5 subtype is 7.9 nM, 
which is around 3-30-fold higher than at α1-, α2- or α3-GABAARs.132 This modest binding selectivity 
is accompanied by efficacy selectivity such that ONO-8590580 attenuated a GABA EC20 current by 
44% whereas there was negligible effects at the other subtypes. The compound gave good hippocampal 
α5-GABAAR occupancy, with the Occ50 being 1.9 mg/kg p.o. and in rat behavioral assays, ONO-
8590580 was able to attenuate MK-801- or scopolamine-induced deficits in performance in the passive 
avoidance and radial arm maze assays but was not anxiogenic nor proconvulsant.132 The development 
status of this or related compounds has not been disclosed but neither this compound nor the α5-
GABAAR NAM mechanism is listed in the company pipeline. 
 
Figure 13. Other compounds. ONO-8590580 and a Saniona compound described in WO 2014/001280 
A1 (44), both of which are α5-GABAAR PAMs acting at the BZD binding site, along with S44819 
which is an α5-GABAAR subtype selective antagonist acting via the GABA (rather than the BZD) 
recognition site.  
 
The Danish company Saniona have published a series of single compound patents (WO 
2014/001278-1282 A1) in which five compounds (typified by 44, Figure 13) all shared a common 
triazole core and had 5-GABAAR affinities ranging from 0.39-87 nM and a reduction of a GABA-
induced current (NAM activity) of between -18 to -39% at this subtype. No selectivity data was 
presented and none of these compounds have been decribed in peer-reviewed journals. Finally, Servier 
have described a benzothiophene compound, S44819 (Egis-13529) which modulates GABAAR function 
by selectively antagonizing the agonist (GABA) binding site of 5-GABAAR.133 It is therefore 
mechanistically different from the other compounds described in this section and is currently being 
evaluated as a therapy to assist post-stroke recovery (NCT02877615).134  
 
4. α5-GABAAR PAMs 
There is an increasing awareness that hippocampal hyperactivity may be a core feature of disorders 
such as schizophrenia.135,33 This hyperactivity is thought to result in an increased output from the 
hippocampus that results in the increased activity of dopaminergic neurons that underlies the disease. 
Moreover, a dysfunction in the regulation of overlapping memories is a core feature of schizophrenia 
that is thought to be associated with α5-GABAARs in the hippocampus.104 These data collectively 




 Figure 14. Structure of imidazobenzodiazepines described as being α5-GABAAR selective PAMs  
 
During the characterization of the imidazobenzodiazepines previously described as α2/α3-GABAARs 
selective PAMs (see above), Cook and colleagues described the properties of SH-053-2′F-R-CH3 and 
SH-053-2′F-S-CH3 (46 and 47, Figure 14) the 4-methyl stereoisomers of JY-XHe-053.93 Both these 
compounds had modest affinity for α5-GABAARs, (95 and 19 nM, for the R and S isomers, respectively) 
that was generally in the region of around 10-fold higher than at the α1, α2 and α3 subtypes (Table 4).93 
 
Table 4. Summary of the in vitro properties of α5-GABAAR PAMs 
Compound Structure 
Ki (nM)  Relative Efficacya 




759 948 769 95  0.25 0.19 0.18 1.19 
SH-053-2′F-S-CH3 468 33 292 19  0.30 0.57 0.31 1.19 
MP-III-022 850 360 660 55  0.11 0.50 0.20 2.48 
GL-II-073 55,000 30,000 63,000 5,000  0.65 bNR NR 1.46 
GL-II-074 1,060 809 1,250 83  1.09 NR NR 1.39 
GL-II-075 542 789 480 79  1.22 NR NR 1.23 
a The efficacy is calculated based upon the potentiation of an EC3-5 GABA concentration of a 1 µM 
concentration of drug relative to the potentiation produced by diazepam, either at a concentration of 1 
µM93 or the average maximum potentiation.135 bNR = not reported. 
 
SH-053-2′F-R-CH3 and SH-053-2′F-S-CH3 have varying degrees of efficacy at α1-, α2- and 
α3-GABAARs, with relative efficacy values ranging from 0.18 to 0.57, but most striking, both 
compounds have efficacy at the α5 subtype that was greater than diazepam. The administration of 
methylazoxymethanol acetate (MAM) to pregnant rats results a changes in the offspring that result in a 
spontaneous dopamine activity within the ventral tegmental area (VTA) that is associated with altered 
activation of the ventral hippocampus.  In this neurodevelopmental of schizophrenia, SH-053-2′F-R-
CH3 reduced the number of spontaneously active dopamine neurons within the VTA, whether the 
compound was administered systemically or infused directly into the hippocampus.136 Moreover, SH-
053-2′F-R-CH3 was able to attenuate the increased sensitivity to amphetamine observed in MAM rats.136 
In a rhesus monkey conflict assay, SH-053-2′F-R-CH3 and SH-053-2′F-S-CH3 produced variable 
effects in individual animals, with the R but not S isomer achieving a significant but modest overall 
anxiolytic effect without showing signs of sedation.93 
The replacement of the ester group in SH-053-2′F-R-CH3 with an amide resulted in the 
identification of MP-III-022 (48, Figure 14) which has a binding affinity across all four subtypes and 
efficacy at the α1- and α3-subtypes comparable to the ester.137 However, MP-III-022 has an increased 
efficacy at the α2 subtype and efficacy at α5-GABAARs was around twice that of SH-053-2′F-R-CH3, 
with a relative efficacy of 2.48 compared to diazepam.93,137 The amide replacement did indeed increase 
the metabolic stability of MP-III-022 relative to SH-053-2′F-R-CH3 in an in vitro rat plasma stability 
assay. However, this in vitro metabolic stability was not reflected in vivo with the ester having an half-
life after i.p. dosing, (75 min) that was twice that of the amide.137 MP-III-022 caused a degree muscle 
relaxation but did not cause sedation, affect anxiety levels or alter the pentylenetetrazole seizure 
threshold.137  
An additional series of amide analogues of SH-053-2′F-R-CH3, GL-II-73 (49, Figure 14), GL-
II-74 and GL-II-75 (50, Figure 14) have been described (together with a fourth compound GL-II-76, 
but no in vitro binding or efficacy data were provided).138 These compounds have a moderate (6-15-
fold) binding selectivity for α5- over α1-, α2- and α3-GABAARs, with GL-II-74 and GL-II-75 having a 
modest α5 affinity (~80 nM) whereas GL-II-73 is very low affinity (5 µM). At a concentration of 1 µM, 
all compounds had PAM activity at all four subtypes with both GL-II-73 and GL-II-74 having efficacy 
at the α1 and α5 subtypes that was comparable to or greater than diazepam.  All three compounds were 
able to show effects in the mouse forced-swim test with GL-II-73 and GL-II-74 (but not GL-II-75) 
having anxiolytic activity in the mouse elevated plus maze with GL-II-73 and GL-II-75. Finally, and 
despite it is much lower GABAAR affinity, GL-II-73 was able to reverse stress- and age-related 
impairments of working memory to a much greater extent than GL-II-75. 138 The data for GL-II-73 have 
been further highlighted139 but in the absence of target engagement (GABAAR occupancy) data, these 
results are difficult to interpret. While the collective data for putative α5-GABAAR PAMs make the 
potential therapeutic relevance of α5-GABAAR PAMs unclear, it is nevertheless worth noting that 
Roche currently have a drug of this mechanism, RG7816, listed in their pipeline as currently undergoing 
Phase 1 clinical studies with a therapeutic indication of autism spectrum disorder. Although no further 
details are currently available regarding RG7816, this is probably the same as RO7017773, for which a 
[11C]RO15-4513 PET study has been conducted in healthy volunteers (NCT03507569).  
5. CONCLUSIONS AND PERSPECTIVES 
It is now approaching 60 years since the introduction of BZDs with their GABAergic, or more 
specifically GABAAR-mediated mechanism of action began to emerge in the mid-1970s.140 
Nevertheless, there continues to be considerable interest in the modulation of GABAARs for a variety 
of CNS and other indications,141 most recently fueled by the approval of Brexanolone as a neurosteroid 
antidepressant.142 However, the main focus on the development of novel GABAAR modulating drugs 
has been on compounds that act via the BZD binding site. Since the start of the millennium there has 
been a convergence of elegant transgenic mouse and subtype-selective pharmacology to provide the 
robust preclinical data that underpins the α2/α3-GABAAR PAM non-sedating anxiolytic and α5-
GABAAR NAMs cognition enhancer hypotheses and it has been rewarding to see representative 
molecules from each of these mechanisms progress into the clinic. However, as with all clinical studies, 
particularly within the neuroscience therapeutic area, the challenge remains in translating preclinical 
science and pharmacology into clinical efficacy and thereafter patient benefit. In this regard, the use of 
[11C]flumazenil or [11C]RO15-4513 PET has proved very useful in establishing clinical target 
engagement (GABAAR occupancy) and selecting a clinical dose. Yet despite this, questions can remain 
regarding the selection of a dose sufficient to test the hypothesis (e.g., PF-06372865 in the chronic back 
pain study) and the correct patient population for establishing efficacy of the mechanism (e.g., is DS 
the most appropriate patient population for evaluating the cognition-enhancing effects of Basmisanil?). 
Layered on top of these issues are the generic issues that plague drug development and halt further 
development such as unexpected preclinical toxicity (e.g., cataract formation with TPA023, 
crystallization of an insoluble metabolite causing renal toxicity with α5IA), variable pharmacokinetics 
and/or poor tolerability (MRK-016) or poor patient compliance (AZD7325). Finally, there are the 
pharma company strategic and/or business decisions that result in what the scientists involved in the 
area are always bound to consider the premature termination of their favorite GABAAR modulator 
projects. The bigger picture, however, it that we have now reached a stage in the GABAAR subtype-
selective modulator story where we have moved on from preclinical data and are now able to discuss 
clinical studies. While there is still a way to go until such compounds, whether they be α2/α3-GABAAR 
PAMs or α5-GABAAR NAMs (or even PAMs) finally reach the market, there is little doubt that such 
molecules have pharmacological profiles that are very distinct from those of BZDs themselves.143 In 
addition, GABAAR modulators may be evaluated using experimental medicine paradigms or a small 
but well characterized patient population. In this latter regard, the use of a small number (seven) of 
photosensitive epilepsy patients to demonstrate efficacy of PF-06372865 is a particularly elegant 
example42 which has redirected the drug, now known as CVL-865, towards being developed as an 
antiepileptic drug. Hence, despite the occasional setbacks, the GABAAR BZD site subtype-selective 
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